← Back to Search

The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology

N/A
Waitlist Available
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Patients from hepatology clinic undergoing new evaluation for NAFLD.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether using the ELF blood test can help doctors better decide when to perform a liver biopsy in patients with high liver enzymes or fatty liver. The ELF test looks for specific markers in the blood that indicate liver damage. By using this test, doctors hope to diagnose more cases of advanced liver scarring or cirrhosis. The Enhanced Liver Fibrosis (ELF) test is a non-invasive blood test that combines three serum markers to assess liver fibrosis severity.

Eligible Conditions
  • Fatty Liver Disease
  • Non-alcoholic Fatty Liver Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
A diagnosis of F3-4 fibrosis based on liver biopsy or clinical diagnosis of cirrhosis.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ELF-testExperimental Treatment1 Intervention
Patients receive ELF testing (a blood draw) and their hepatologist receives the result within a week.
Group II: ControlActive Control1 Intervention
No intervention.

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
517 Previous Clinical Trials
176,848 Total Patients Enrolled
Gilead SciencesIndustry Sponsor
1,137 Previous Clinical Trials
867,533 Total Patients Enrolled
~86 spots leftby Dec 2025